A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)

NCT02266927 | Completed Phase 1

• 1 other identifier: OPN-FLU-1102
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

To compare the systemic exposure of a single dose of 400 µg of OPTINOSE FLUTICASONE with 440 µg of Flovent® HFA (fluticasone propionate) Inhalation Aerosol in asthmatic subjects.

Conditions

Mild to Moderate Asthma

Outcome Measures

Primary Outcomes (1)

• The ratio of least-squares means of the ln transformed PK parameter AUC0-∞ is the primary endpoint.

  Part 2

  Pre-dose and at 0.167, 0.333, 0.5, 0.75, 1, 1.333, 1.667, 2, 2.5, 3, 4, 6, 9, 12, 16, 24, and 36 hours after dosing

Study Arms (2)

Flovent® HFA 440µg

ACTIVE COMPARATOR

Flovent® HFA (fluticasone propionate) Inhalation Aerosol 440 µg

Drug: Flovent HFA

OPTINOSE™ FLUTICASONE 400µg intranasal

EXPERIMENTAL

OPTINOSE™ FLUTICASONE, single dose of 400 µg intranasally

Drug: OPTINOSE™ FLUTICASONE

Interventions

Flovent HFA DRUG

Flovent® HFA 440µg

OPTINOSE™ FLUTICASONE DRUG

OPTINOSE™ FLUTICASONE 400µg intranasal

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Male or female subjects' ages 18 to 55 years, inclusive, at screening.
• Have a body mass index of 18 to 32 kg/m2, inclusive, and a body weight of not less than 52 kg for males and 45 kg for females.
• Otherwise healthy mild to moderate asthmatic (Part 2) with no clinically relevant abnormalities in the opinion of the Investigator as determined by medical history, physical examination, blood chemistry, hematology (including complete blood count), serology, urinalysis, vital signs, and ECG performed at screening.
• History of mild to moderate asthma, diagnosed by a physician, which is well controlled at the present time (no history of sudden or severe asthma exacerbation in the past 12 months).
• Are unlikely to exacerbate during the study due to seasonal allergen exposure.
• Able to tolerate withdrawal of their medication for a required period of time.

You may not qualify if:

• Currently have or have a history of disease or dysfunction of the cardiovascular, endocrine, hematologic, neurological, immune, gastrointestinal, genitourinary, musculoskeletal, or other body system that is clinically significant in the opinion of the Investigator.
• History of smoking or use of nicotine-containing substances within the previous 3 months before screening.
• Hypersensitivity to fluticasone propionate or any of the excipients found in OPTINOSETM FLUTICASONE or Flovent® HFA (for Part 2).
• History of extensive nasal and/or sinus surgery.
• Known nasal obstruction including allergic rhinitis, nasal septal deviations, polyposis, severe mucosal swelling, nasal ulcers, nasal trauma or any other reason.
• History of acute severe asthma attacks.
• History of seasonal asthma exacerbation, in which case subjects should be outside the relevant allergen season.
• Have evidence of any chronic medical conditions other than asthma requiring prescription medications (e.g., hypertension or diabetes).
• Have used inhaled, intranasal, oral, or injectable corticosteroids within 4 weeks prior to dosing. Subjects should be on stable treatment for at least 1 month prior to withdrawal.

Sponsors & Collaborators

• Optinose US Inc.: lead

Study Sites (1)

Celerion

Belfast, BT9 6AD, Ireland

Location

Related Publications (1)

• Messina JC, Offman E, Carothers JL, Mahmoud RA. A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol. Clin Ther. 2019 Nov;41(11):2343-2356. doi: 10.1016/j.clinthera.2019.09.013. Epub 2019 Nov 12.

  PMID: 31732149 DERIVED

MeSH Terms

Interventions

Fluticasone

Intervention Hierarchy (Ancestors)

Androstadienes; Androstenes; Androstanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds

Study Officials

• Adrian J Stewart, BM, MRCGP, MFPM

  Celerion

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 7, 2014
• First Posted: October 17, 2014
• Study Start: September 1, 2014
• Primary Completion: March 1, 2015
• Study Completion: April 1, 2015
• Last Updated: February 3, 2016

Record last verified: 2016-02

Locations

IE (1)